Novo targets over $23 billion in risk-adjusted pipeline sales by 2035, excluding any contribution from future acquisitions.
NVO tumbled about 8% as its Capital Markets Day failed to convince investors despite plans for more than five "multi-blockbusters" by 2030.
Viking's injectable VK2735 produced up to… [+5159 chars]
Discussion (0)
No comments yet. Be the first to share your thoughts!
Join the Conversation
You need to be logged in to leave a comment.
Sign In Create Account